Clinical Trial Update: Study of TAK-672 in Participants With Acquired Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

Takeda's TAK-672 study in Acquired Hemophilia A (Phase 2/3) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Hemophilia

Drugs mentioned

• TAK-672

Snippet

Sponsor: Takeda | Conditions: Acquired Hemophilia A | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-12-02